This clinical trial is focused on studying a type of cancer called Relapsed/Refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). This is a condition where the cancer has either returned after treatment or has not responded to initial treatments. The study is evaluating a treatment called Axicabtagene Ciloleucel, also known as Axi-Cel, which is a form of cell therapy. This treatment involves modifying a patient’s own immune cells to better fight the cancer. The study also involves the use of other medications, Fludarabine Phosphate and Cyclophosphamide, which are used to prepare the body for the main treatment.

The purpose of the study is to assess how well Axi-Cel works as a second-line therapy for patients who cannot undergo a procedure called autologous stem cell transplantation. This is a treatment option that uses a patient’s own stem cells to help recover from high-dose chemotherapy. The study will monitor the patients’ response to the treatment over a period of time, specifically looking at the complete metabolic response, which is a measure of how much the cancer has decreased or disappeared, at three months after receiving Axi-Cel.

Participants in the study will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will track the progress of the participants at various intervals to see how the treatment affects their cancer and overall health. The goal is to gather information on the effectiveness and safety of Axi-Cel in treating this type of lymphoma. The study is expected to continue until 2025, providing valuable insights into this promising treatment option.